8-K
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_____________________
FORM
8-K
_____________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): September 9, 2008
_____________________
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
_____________________
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
ITEM
7.01
|
REGULATION
FD DISCLOSURE.
|
On September
9, 2008, Oramed Pharmaceuticals Inc. (“Oramed”) issued a press release announcing that it has entered
into an agreement with ETI Karle Clinical Pvt. Ltd., a clinical research
organization in India to conduct Phase 2B clinical trials on its oral insulin
capsules. A copy of the press release is being furnished with this report as Exhibit 99.1 and is incorporated herein by
reference.
As
previously disclosed, Oramed, in conjunction
with the Diabetes Unit, Hadassah University Hospital, was selected to display
its abstract, entitled "Open Label Study to Assess the Safety, Pharmacokinetics
(PK) and Pharmacodynamics (PD) of Five Oral Insulin Formulations in Healthy
Subjects," at the 44th Annual Meeting of the European Association for the
Study of Diabetes (EASD) held on September 9, 2008 in Rome, Italy A
copy of the abstract is being furnished with this report as Exhibit 99.2 and is incorporated herein by reference.
Pursuant
to the rules of the Securities and Exchange Commission, the information
contained in this report (including the exhibits) shall not be deemed to be
“filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,
as amended, and will not be incorporated by reference into any filing by Oramed
under such Act or the Securities Act of 1933, as amended.
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
|
|
Press
Release dated September 9, 2008
|
|
|
Oramed
Pharmaceuticals Inc. Abstract Entitled “Open Label Study to Assess the
Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Five Oral
Insulin Formulations in Healthy Subjects.”
|
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
ORAMED
PHARMACEUTICALS INC.
|
Dated:
September 9, 2008
|
|
|
|
|
|
By:
|
/s/
Nadav Kidron
|
|
|
|
Nadav
Kidron
|
|
|
|
President,
CEO and Director
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|